SG10201908388UA - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Google Patents

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Info

Publication number
SG10201908388UA
SG10201908388UA SG10201908388UA SG10201908388UA SG 10201908388U A SG10201908388U A SG 10201908388UA SG 10201908388U A SG10201908388U A SG 10201908388UA SG 10201908388U A SG10201908388U A SG 10201908388UA
Authority
SG
Singapore
Prior art keywords
apoptosis
immune
cancer
treatment
autoimmune diseases
Prior art date
Application number
Inventor
Zhi-Fu Tao
Xilu Wang
Michael Wendt
Andrew Souers
Andrew Judd
Aaron Kunzer
Gerard Sullivan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51529947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201908388U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201908388UA publication Critical patent/SG10201908388UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl- 2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. [No Suitable Figure]
SG10201908388U 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases SG10201908388UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781070P 2013-03-14 2013-03-14
US14/176,506 US20140275082A1 (en) 2013-03-14 2014-02-10 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Publications (1)

Publication Number Publication Date
SG10201908388UA true SG10201908388UA (en) 2019-10-30

Family

ID=51529947

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507363UA SG11201507363UA (en) 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201908388U SG10201908388UA (en) 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201507363UA SG11201507363UA (en) 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Country Status (36)

Country Link
US (6) US20140275082A1 (en)
EP (2) EP2970257B1 (en)
JP (4) JP6449222B2 (en)
KR (2) KR102260645B1 (en)
CN (2) CN105026394B (en)
AR (2) AR095263A1 (en)
AU (2) AU2014242104B2 (en)
BR (1) BR112015021115B1 (en)
CA (2) CA3110552A1 (en)
CL (2) CL2015002640A1 (en)
CR (1) CR20150510A (en)
CY (1) CY1120862T1 (en)
DK (1) DK2970257T3 (en)
DO (1) DOP2018000026A (en)
ES (1) ES2689679T3 (en)
GT (1) GT201500248A (en)
HK (1) HK1220189A1 (en)
HR (1) HRP20181403T8 (en)
HU (1) HUE038983T2 (en)
IL (3) IL240010B (en)
LT (1) LT2970257T (en)
MX (1) MX360541B (en)
MY (1) MY178821A (en)
NZ (1) NZ631701A (en)
PE (2) PE20191555A1 (en)
PL (1) PL2970257T4 (en)
PT (1) PT2970257T (en)
RS (1) RS57750B1 (en)
RU (2) RU2662812C2 (en)
SG (2) SG11201507363UA (en)
SI (1) SI2970257T1 (en)
TW (2) TWI717662B (en)
UA (1) UA120035C2 (en)
UY (1) UY35406A (en)
WO (1) WO2014158528A1 (en)
ZA (1) ZA201505203B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
KR20140119023A (en) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 Methods for improving medical therapies
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
MX2021012208A (en) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
JP6688224B2 (en) 2014-01-28 2020-04-28 バック インスティテュート フォー リサーチ オン エイジング Treatment of osteoarthritis in joints by administration of means that inhibit MDM2
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
MX2016012021A (en) 2014-03-19 2017-04-13 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders.
PE20170438A1 (en) 2014-09-12 2017-04-28 Boehringer Ingelheim Int SPIROCYCLIC INHIBITORS OF CATEPSIN C
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104370905B (en) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 The synthesis of Bcl-2 AB combined inhibitor T-199
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
PE20181358A1 (en) 2015-12-04 2018-08-22 Novartis Ag COMPOSITIONS OF ANTIBODY GRAFTED WITH CYTOKINE AND METHODS FOR ITS USE IN IMMUNOREGULATION
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
BR112018067550A2 (en) * 2016-02-27 2019-10-01 Hpvvax Llc methods for treating a patient who has skin cancer, benign or cancerous tumor or a human papillomavirus (hpv) -associated lesion, and pharmaceutical composition
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018041248A1 (en) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2 selective inhibitor and preparation and use thereof
US11053239B2 (en) * 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
KR102630069B1 (en) 2017-04-18 2024-01-26 포천 파마슈티컬즈, 엘티디. Apoptosis-inducing agent
CN110759908B (en) * 2017-06-26 2021-03-12 深圳市塔吉瑞生物医药有限公司 N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof
CN118084904A (en) 2018-01-10 2024-05-28 里科瑞尔姆Ip控股有限责任公司 Benzamide compounds
CN117430601A (en) 2018-04-29 2024-01-23 百济神州有限公司 Bcl-2 inhibitors
CN110577525A (en) * 2018-06-11 2019-12-17 北京万全德众医药生物技术有限公司 preparation method of vernetulara intermediate
WO2020088442A1 (en) 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
CN114057728A (en) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 Heterocyclic compounds as BCL-2 inhibitors
WO2022037684A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
EP4298098A1 (en) * 2021-02-01 2024-01-03 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
CN113046433B (en) * 2021-03-19 2022-12-02 武汉大学 Application of cytokine IL1F9 in preparation of products for detecting, preventing and treating tumors
CN115260191B (en) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 Piperidine compound and preparation method and application thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
ATE257829T1 (en) 1995-09-15 2004-01-15 Upjohn Co AMINOARYL OXAZOLIDINONE N-OXIDE
MX336813B (en) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Human antibodies that bind human tnf alpha.
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
RU2001103044A (en) 1998-07-06 2003-08-10 Бристол-Маерс Сквибб Ко. (Us) Benylsulfonamides as dual antagonists of angiotensin endothelin receptors
DE19913692A1 (en) 1999-03-25 2000-09-28 Basf Ag Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances
DE19929361A1 (en) 1999-06-25 2001-01-04 Basf Ag Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
JP4234344B2 (en) 1999-12-28 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sulfonamide-containing heterocyclic compounds
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EA005810B1 (en) 2001-06-06 2005-06-30 Эли Лилли Энд Компани Benzoylsulfonamides and sulfonylbenzamidines for use as antitumor agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
BRPI0307786B8 (en) 2002-02-26 2021-05-25 Astrazeneca Ab pharmaceutical composition, method of preparing the same, methods of inhibiting the rate of precipitation of the agent from solution in the gi tract, and to reduce inter-patient variability with respect to bioavailability and/or plasma concentrations of the agent, and, use of a water-soluble cellulose ether or an ester of a water-soluble cellulose ether
KR20040086452A (en) 2002-02-26 2004-10-08 아스트라제네카 아베 Novel crystalline forms of the anti-cancer compound zd1839
FR2836914B1 (en) 2002-03-11 2008-03-14 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Tetrahydropyranyl cyclopentyl tetrah- ydropyridopyrdine modulators of chemohne receptor activity.
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
ES2306216T3 (en) 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SOLID DISPERSIONS FOR CANCER TREATMENT.
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc Novel cyclosporin analogues and their pharmaceutical uses
FR2884821B1 (en) * 2005-04-26 2007-07-06 Aventis Pharma Sa SUBSTITUTED PYRROLOPYRIDINES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
JP5132550B2 (en) 2005-05-12 2013-01-30 アボット・ラボラトリーズ Apoptosis promoter
EP1896470B1 (en) 2005-05-16 2010-05-26 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
CN101534904B (en) 2006-09-05 2013-11-06 Abbvie公司 BCL inhibitors treating platelet excess
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2460725C2 (en) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Novel 2-aminooxazolines as taar1 ligands
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
MX2010003548A (en) 2007-10-01 2010-06-02 Univ Johns Hopkins Methods of treating neurological autoimmune disorders with cyclophosphamide.
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
CN101969951B (en) 2007-11-16 2012-10-31 雅培制药有限公司 Method of compound in preparing medicine for treating arthritis
EP2219651A1 (en) 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
MX2011003740A (en) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Pharmaceutical formulation 514.
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (en) 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102307872B (en) 2008-12-05 2016-06-15 Abbvie公司 Selectively bring out the sulfamide derivative of Apoptosis medicament as the BCL-2-that is used for the treatment of cancer and immunological diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
GB2466622A (en) * 2008-12-23 2010-06-30 Trinity College Dublin Alpha2-Adrenoceptor Ligands
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
AU2010204554B2 (en) 2009-01-19 2013-05-30 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2010204555B2 (en) 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI476195B (en) * 2009-05-26 2015-03-11 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (en) 2009-06-08 2016-07-01 亞培公司 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
JP6068352B2 (en) * 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド Solid dispersion containing apoptosis inducer
PT2642999T (en) * 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
PT2643322T (en) 2010-11-23 2017-11-13 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
BR112015021115A2 (en) 2017-10-10
DK2970257T3 (en) 2018-09-10
US10081628B2 (en) 2018-09-25
CR20150510A (en) 2015-12-11
TWI675835B (en) 2019-11-01
PE20151555A1 (en) 2015-12-06
TWI717662B (en) 2021-02-01
PT2970257T (en) 2018-10-25
US20200331907A1 (en) 2020-10-22
RU2018127315A3 (en) 2021-10-05
US20170008891A1 (en) 2017-01-12
AR117768A2 (en) 2021-08-25
HUE038983T2 (en) 2018-12-28
CA3110552A1 (en) 2014-10-02
US20150299197A1 (en) 2015-10-22
MY178821A (en) 2020-10-20
EP2970257B1 (en) 2018-05-30
IL287315A (en) 2021-12-01
RU2015143917A (en) 2017-04-18
JP2020180145A (en) 2020-11-05
CN107987075A (en) 2018-05-04
JP6449222B2 (en) 2019-01-09
JP2019038820A (en) 2019-03-14
HK1220189A1 (en) 2017-04-28
LT2970257T (en) 2018-09-25
MX360541B (en) 2018-10-19
CN105026394A (en) 2015-11-04
IL265296A (en) 2019-05-30
US20140275082A1 (en) 2014-09-18
AU2018226476C1 (en) 2020-01-16
EP2970257A1 (en) 2016-01-20
MX2015011641A (en) 2015-12-16
CN105026394B (en) 2017-12-29
RS57750B1 (en) 2018-12-31
SI2970257T1 (en) 2018-10-30
RU2018127315A (en) 2019-03-13
CL2015002640A1 (en) 2016-03-18
ZA201505203B (en) 2016-07-27
ES2689679T3 (en) 2018-11-15
IL240010B (en) 2019-09-26
DOP2018000026A (en) 2018-10-31
HRP20181403T8 (en) 2018-12-28
IL240010A0 (en) 2015-09-24
AU2014242104A1 (en) 2015-07-30
PL2970257T4 (en) 2019-01-31
CY1120862T1 (en) 2019-12-11
CN107987075B (en) 2020-12-01
NZ631701A (en) 2017-05-26
JP2021167330A (en) 2021-10-21
AR095263A1 (en) 2015-09-30
GT201500248A (en) 2017-09-14
KR20210021613A (en) 2021-02-26
HRP20181403T1 (en) 2018-11-30
KR20150130486A (en) 2015-11-23
US20180354952A1 (en) 2018-12-13
CA2899041A1 (en) 2014-10-02
US20210403467A1 (en) 2021-12-30
TW201524976A (en) 2015-07-01
UY35406A (en) 2014-09-30
UA120035C2 (en) 2019-09-25
AU2014242104B2 (en) 2018-07-05
CL2018000353A1 (en) 2018-07-13
AU2018226476A1 (en) 2018-09-27
PL2970257T3 (en) 2018-11-30
JP2016517406A (en) 2016-06-16
RU2662812C2 (en) 2018-07-31
EP3415514A1 (en) 2018-12-19
BR112015021115B1 (en) 2022-05-03
PE20191555A1 (en) 2019-10-24
SG11201507363UA (en) 2015-10-29
AU2018226476B2 (en) 2019-10-10
TW201908316A (en) 2019-03-01
WO2014158528A1 (en) 2014-10-02
KR102260645B1 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12018501264A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JOP20200192A1 (en) Anti-tigit antibodies
SG185638A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2019012154A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
UA106403C2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA112326C2 (en) APOPTOSIS CAUSES FOR TREATMENT OF Malignant Neoplasms And Immune And Autoimmune Diseases
SG10201406608YA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX360172B (en) Apoptosis-inducing agents.
MX351970B (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2017009608A (en) Anti-cancer compounds.
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.
IN2013MU03118A (en)